Thymosin α1

Source: Wikipedia, the free encyclopedia.
PTMA
Gene ontology
Molecular function
Cellular component
Biological process
Sources:Amigo / QuickGO
Ensembl
UniProt
RefSeq (mRNA)

NM_001099285
NM_002823

n/a

RefSeq (protein)

NP_001092755
NP_002814

n/a

Location (UCSC)Chr 2: 231.71 – 231.71 Mbn/a
PubMed search[2]n/a
Wikidata
View/Edit Human

Thymosin α1 is a

peptide fragment derived from prothymosin alpha, a protein that in humans is encoded by the PTMA gene.[3]

It was the first of the peptides from Thymosin Fraction 5 to be completely sequenced and synthesized. Unlike β thymosins, to which it is genetically and chemically unrelated, thymosin α1 is produced as a 28-amino acid fragment, from a longer, 113-amino acid precursor, prothymosin α.[4]

Function

Thymosin α1 is believed to be a major component of Thymosin Fraction 5 responsible for the activity of that preparation in restoring immune function in animals lacking thymus glands. It has been found to enhance cell-mediated immunity in humans as well as experimental animals.[5]

Therapeutic application

As of 2009 Thymosin α1 is approved in 35 under-developed or developing countries for the treatment of Hepatitis B and C, and it is also used to boost the immune response in the treatment of other diseases.[6][7]

Clinical studies

Clinical trials suggest it may be useful in cystic fibrosis,

chronic hepatitis B.[8]

It has been studied for possible use in treating cancer (e.g. with chemotherapy).[9]

See also

  • Thymosins

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000187514 - Ensembl, May 2017
  2. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  3. PMID 1612591
    .
  4. .
  5. .
  6. .
  7. ^ .
  8. .
  9. .

Further reading